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Left Atrial Function in Mitral Regurgitation
Guilt by Association*Robert O. Bonow, MD, MSChicago, IllinoisDespite decades of study and literally hundreds of
papers in the medical literature, the management of
patients with mitral regurgitation (MR) caused by
myxomatous mitral valve disease remains the subject
of ongoing uncertainty and controversy (1–3).
Current indications for surgical intervention that
rely on symptoms, left ventricular (LV) systolic
function, atrial ﬁbrillation, and pulmonary artery
pressure, which are embedded in the American and
European practice guidelines (4,5), are based on
evidence that these subjective and objective markersSee page 225of disease severity have a demonstrable impact on
patient outcomes. It is also understood that when
signiﬁcant symptoms, LV dysfunction, atrial ﬁbril-
lation, and/or pulmonary hypertension develop in
patients, their survival and functional results after
mitral valve repair are suboptimal compared with
patients who undergo surgery earlier in the natural
history of the disease (1,3,6–9). This has resulted in
a trend toward earlier referral for surgery in patients
with severe MR, even if they are asymptomatic with
preserved systolic function, when there is a high
likelihood of successful and durable mitral valve
repair (4). It is further recognized that additional
objective markers indicative of outcome would help
greatly in reﬁning this complex clinical decision-
making process.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Center for Cardiovascular Innovation, Department of Medicine,
Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Dr. Bonow has reported that he has no relationships relevant to the con-
tents of this paper to disclose.For such a new marker to fulﬁll this need, it must
be shown to be independent of the existing markers
and provide incremental information regarding pa-
tient outcomes above and beyond that provided by
the existing markers. That is, it must be useful in
identifying patients who will beneﬁt from early
surgery who are not already so identiﬁed based on
the established indications for surgery. This is not
an issue for managing mitral valve disease alone but
is true in diagnostic testing in all areas of cardio-
vascular medicine, in which novel risk markers
should have calibration (correctly identifying the
proportion of patients who will have an event) and
discrimination (distinguishing between patients at
higher and lower risk) and thus reclassify patients
according to risk (10). Examples of this effect
include C-reactive protein and coronary calcium
scoring in reclassifying the risk of coronary heart
disease events beyond the Framingham risk score
(11,12). The study by Ring et al. (13) in this issue of
iJACC, proposing that measures of left atrial func-
tion can serve as a guide to optimal timing of surgery
for myxomatous MR, fails to achieve this standard.
This study reports associations between left atrial
function and the conventional indications for sur-
gery, but does not show incremental diagnostic or
prognostic value, and it provides no outcome data.
For several years, the response of the left atrium to
chronic severe MR has been a focus of investigation
(14,15), moving beyond the more customary as-
sessments of LV volume and function, quantiﬁca-
tion of MR severity, and pulmonary artery pressure.
The magnitude of left atrial dilation has been shown
to be a determinant of outcome in patients with
severe MR that is additive to the standard in-
dications for surgery (16,17). As a result, severe left
atrial dilation on echocardiography (>60 ml/m2)
appeared as a new Class IIb recommendation for
consideration for surgical mitral valve repair in the
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2342012 guidelines of the European Society of Cardi-
ology (5).
In the current paper, Ring et al. (13) further
explore the left atrial response to chronic myxoma-
tous MR by assessing left atrial contractile function
in patients with mild to moderate MR, asymp-
tomatic patients with severe MR without standard
indications for surgery, and patients with severe
MR who fulﬁlled criteria for surgery. Using
2-dimensional echocardiography and 2-dimensional
speckle tracking, they report that left atrial ejection
fraction and left atrial strain patterns are “indepen-
dent predictors” of indications for surgery and
conclude that assessment of left atrial function by
echocardiography is an additional tool to guide the
optimal timing of surgery for myxomatous MR.
Ring et al. (13) have shown interesting and
noteworthy associations between left atrial function
and the currently accepted consensus-driven in-
dicators for surgery. However, these are associations
only, and they have not shown that the measures of
left atrial function are predictive of outcome or that
they provide incremental diagnostic or prognostic
potential to guide management. The terms predict
and independent are used very loosely in a cross-
sectional study with no follow-up information.
The patients who fulﬁlled standard criteria for sur-
gery were older and more symptomatic and had
worse LV function (mean end-systolic dimension of
50 mm), higher pulmonary artery systolic pressures,
and markedly greater left atrial volumes (mean
71 ml/m2). Thus, it should come as no surprise that
other measures of disease severity, such as left atrial
contractile function, were more abnormal in this
group. One does not need some new index to
recognize these patients as being sicker and needing
surgery. But how well do the left atrial function data
behave in the asymptomatic group who do not
already have indications for surgery in actuallypredicting who will either develop indications for
surgery in the future or have a worse outcome?
Thus, the current paper provides the basis for
future work to explore the potential of left atrial
functional assessment in guiding management de-
cisions. However, it is an overly zealous interpreta-
tion of the current state of knowledge to suggest
that these measurements represent a new predictive
instrument when there has been no attempt to tie
them to outcomes. Unfortunately, the authors use
the term predict in its various iterations 14 times,
and independent is repeated 11 times. The associa-
tion with the other established predictors of poor
outcome is not evidence of an independent new
predictor because, by deﬁnition, the new variables are
dependent on the existing predictors. The demon-
stration that patients who are older, sicker (more
symptomatic), and with worse LV function and
higher pulmonary artery pressures also have worse
left atrial function does not lead to the conclusion
that assessment of left atrial function is an indepen-
dent predictor of the need for surgery. What is now
needed is further application of these novel mea-
surements to a younger, less sick population being
followed serially to determine whether they indeed
predict the need for surgery above and beyond the
customary variables. Also, do these measurements
predict poor outcome after surgery in some manner
not predicted by age, symptoms, LV size and func-
tion, and pulmonary artery pressure? This challenge
should be the basis for future studies to determine
whether these indexes actually do provide indepen-
dent, incremental value in patient management.Reprint requests and correspondence: Dr. Robert O.
Bonow, Center for Cardiovascular Innovation, Depart-
ment of Medicine, Northwestern University Feinberg
School of Medicine, 201 East Huron Street, Galter 3-150,
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